Literature DB >> 21378994

Prolene frontalis suspension in paediatric ptosis.

K Chow1, N Deva, S G J Ng.   

Abstract

AIM: The aim of this study was to assess the efficacy of frontalis suspension using 4-0 prolene sutures for paediatric ptosis with poor levator function. PATIENTS AND METHODS: A retrospective chart review was performed on children who underwent 4-0 prolene frontalis suspension from 2000 to 2008 with a minimum of 6 months' follow-up. Functional success was defined when three criteria were met: (a) satisfactory lid height (defined as margin-to-reflex distance ≥3 mm with minimal frontalis muscle tone); (b) satisfactory lid symmetry (≤2 mm asymmetry in margin-to-reflex distance); and (c) satisfactory cosmesis. Recurrence was defined by a drop in lid height of ≥3 mm from the initial post-operative level.
RESULTS: A total of 23 patients (30 eyelids) were included. The mean follow-up duration was 28.7 months (range 6.3 to 100 months). The functional success rate was 74% (17/23 patients). Ptosis recurred in 22% (5/23) of patients. Only one patient (4%) developed a complication: a case of minor wound infection.
CONCLUSIONS: In paediatric ptosis with poor levator function, prolene frontalis suspension has good efficacy and an excellent safety profile. The results of prolene frontalis suspension are comparable to those of other non-autogenous materials.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21378994      PMCID: PMC3178123          DOI: 10.1038/eye.2011.32

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  19 in total

1.  Long-term efficacy of 2-0 Prolene brow suspensions for congenital ptosis.

Authors:  H Garrott; P Aristodemou; N Sinclair; C Lane; R Harrad
Journal:  Eye (Lond)       Date:  2009-10-09       Impact factor: 3.775

2.  Blepharoptosis correction with frontalis suspension using a supramid sling: duration of effect.

Authors:  D Liu
Journal:  Am J Ophthalmol       Date:  1999-12       Impact factor: 5.258

3.  Mersilene mesh brow suspension: efficiency and complications.

Authors:  C R Hintschich; M Zürcher; J R Collin
Journal:  Br J Ophthalmol       Date:  1995-04       Impact factor: 4.638

4.  Treatment of congenital ptosis with frontalis suspension: a comparison of suspensory materials.

Authors:  R S Wagner; J A Mauriello; L B Nelson; J H Calhoun; J C Flanagan; R D Harley
Journal:  Ophthalmology       Date:  1984-03       Impact factor: 12.079

5.  Congenital ptosis: results of surgical management.

Authors:  G M Whitehouse; J R Grigg; F J Martin
Journal:  Aust N Z J Ophthalmol       Date:  1995-11

6.  Correction of severe blepharoptosis.

Authors:  W Deenstra; P Melis; M Kon; P Werker
Journal:  Ann Plast Surg       Date:  1996-04       Impact factor: 1.539

Review 7.  Functional results and complications of Mersilene mesh use for frontalis suspension ptosis surgery.

Authors:  P Mehta; P Patel; J M Olver
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

8.  Congenital ptosis. Long-term results of treatment using lyophilized fascia lata for frontalis suspensions.

Authors:  M E Wilson; R W Johnson
Journal:  Ophthalmology       Date:  1991-08       Impact factor: 12.079

9.  The use of Prolene as a temporary suspensory material for brow suspension in young children.

Authors:  R M Manners; A G Tyers; R J Morris
Journal:  Eye (Lond)       Date:  1994       Impact factor: 3.775

10.  Silicone frontalis slings for the correction of blepharoptosis: indications and efficacy.

Authors:  S R Carter; W J Meecham; S R Seiff
Journal:  Ophthalmology       Date:  1996-04       Impact factor: 12.079

View more
  2 in total

1.  Factors Affecting the Outcome of Frontalis Sling Surgery in Patients with Severe Blepharoptosis.

Authors:  Amer S Al Mansory
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-09-24

2.  Postoperative Visual Outcome: Sling procedure with prolene sutures in children with simple congenital ptosis.

Authors:  Nida Shamim; Nausheen Hayat; Alyscia Cheema
Journal:  Pak J Med Sci       Date:  2022 Jan-Feb       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.